NCT07070323View on ClinicalTrials.gov

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
T-Cell Acute Lymphocytic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies
Interventions
DRUG

Autologous CD5 CAR T-cells

Peripheral blood mononuclear cells for the production of CD5 CAR T-cells from patients.

DRUG

Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells

Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from previous SCT donors.

DRUG

Newly matched donor-derived CD5 CAR T-cells

Peripheral blood mononuclear cells for the production of CD5 CAR T cells are collected from newly matched donors.

Trial Locations (4)

102206

RECRUITING

Beijing GoBroad Hospital, Beijing

200435

RECRUITING

Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, Shanghai

201418

RECRUITING

Shanghai Liquan Hospital, Shanghai

610083

NOT_YET_RECRUITING

The General Hospital of Western Theater Command PLA, Chengdu

All Listed Sponsors
collaborator

The General Hospital of Western Theater Command

OTHER

collaborator

Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

OTHER

collaborator

Shanghai Liquan Hospital

OTHER

lead

Beijing GoBroad Hospital

OTHER

NCT07070323 - A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies | Biotech Hunter | Biotech Hunter